Spruce Biosciences, Inc. (SPRB)
60.78
-2.52
(-3.98%)
USD |
NASDAQ |
Aug 28, 16:00
60.60
-0.18
(-0.30%)
After-Hours: 20:00
Spruce Biosciences Debt to Equity Ratio : 0.0916 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0916 |
| March 31, 2026 | 0.2056 |
| December 31, 2025 | 0.0173 |
| September 30, 2025 | 0.2503 |
| June 30, 2025 | 0.1383 |
| March 31, 2025 | 0.1498 |
| December 31, 2024 | 0.0959 |
| September 30, 2024 | 0.0626 |
| June 30, 2024 | 0.0624 |
| March 31, 2024 | 0.0623 |
| December 31, 2023 | 0.0602 |
| September 30, 2023 | 0.0593 |
| June 30, 2023 | 0.0571 |
| March 31, 2023 | 0.0552 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0922 |
| September 30, 2022 | 0.0752 |
| June 30, 2022 | 0.0672 |
| March 31, 2022 | 0.0607 |
| December 31, 2021 | 0.0586 |
| September 30, 2021 | 0.0552 |
| June 30, 2021 | 0.0513 |
| March 31, 2021 | 0.0479 |
| December 31, 2020 | 0.0427 |
| September 30, 2020 | 0.0996 |
| June 30, 2020 | 0.1521 |
| March 31, 2020 | |
| December 31, 2019 | -1.574 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Biogen, Inc. | 0.4433 |
| PTC Therapeutics, Inc. | -4.212 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 102.85M |
| Total Liabilities (Quarterly) | 19.12M |
| Shareholders Equity (Quarterly) | 83.73M |
| Current Ratio | 9.227 |
| Net Debt Paydown Yield | -0.72% |